Basilea Pharmaceutica AG (OTC:BPMUF) Q2 2025 Earnings Conference Call August 19, 2025 10:00 AM ET
Company Participants
Adesh Kaul – Chief Financial Officer
David Veitch – Chief Executive Officer
Marc Engelhardt – Chief Medical Officer
Conference Call Participants
Brian Templeton White – Calvine Partners LLP
Jyoti Prakash – Edison Investment Research Limited
Laurent Flamme – Zürcher Kantonalbank, Research Division
Raghuram Selvaraju – H.C. Wainwright & Co, LLC, Research Division
Thomas Meyer – Baader-Helvea Equity Research
Operator
Ladies and gentlemen, welcome to the Basilea Pharmaceutica Half Year Results 2025 Conference Call and Live Webcast. I am Sandra, the Chorus Call operator. [Operator Instructions] The conference is being recorded. The presentation will be followed by a Q&A session. [Operator Instructions] The conference must not be recorded for publication or broadcast. At this time, it’s my pleasure to hand over to David Veitch, Chief Executive Officer. Please go ahead, sir.
David Veitch
Thank you. Hello. I’m David Veitch, CEO of Basilea. Thank you for joining us today on our conference call and webcast. We’re going to review our financial results and key achievements for the first half year 2025 as well as highlight our priorities going forwards. For further detailed information, please see the ad hoc announcement issued this morning at our half year report. These documents are both available on our website at basilea.com. I would like to mention that this call contains certain forward-looking statements. Joining me on our call today are Adesh Kaul, our Chief Financial Officer; and Dr. Marc Engelhardt, our Chief Medical Officer.
Before we dive into the detailed portfolio update and financial performance, I would like to start with our key achievements since the beginning of the year. This period has truly been a remarkable time for Basilea. We have made outstanding progress across all dimensions of our business from
Read the full article here
